Table 2.

Clinical trials employing γ-secretase inhibitors in the treatment of breast cancer

Name	Target	Type of study	Trial ID*
Individual therapy
MK-0752 (Merck and Co, whitehouse Station, NJ, USA)	Metastatic or locally advanced breast cancer	Phase I	NCT00106145
PF03084014 (Pfizer, Groton, CT, USA)	Advanced solid tumors	Phase I	NCT00878189
RO-4929097 (Roche, Nutley, NJ, USA)	Advanced or metastatic breast cancer or recurrent triple negative breast cancer	Phase II	NCT01151449
Combination therapy
MK-0752 + Docetaxel	Locally advanced or metastatic breast cancer	Phase I/II	NCT00645333
MK-0752 + Tamoxifen or Letrozole	Early stage breast cancer	Pilot study	NCT00756717
Ridaforolimus (MK-8669) with either MK-0752 or MK-2206 (Akt inhibitor)	Advanced solid tumor	Phase I	NCT01295632
RO-4929097 + Capecitabine	Refractory solid tumors	Phase I	NCT01158274
RO-4929097 + Cediranib maleate	Advanced solid tumors	Phase I clinical trial	NCT01131234
RO-4929097 + Letrozole	Post-menopausal ER+/PR+ Stage I or II breast cancer	Phase Ib clinical trial	NCT01208441
RO-4929097 + Vismodegib	Metastatic breast cancer	Phase I clinical trial	NCT01071564
RO-4929097 + Paclitaxel + Carboplatin	Stage II or III triple negative breast cancer	Phase I clinical trial	NCT01238133

Note:

^*clinicaltrials.gov.

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.